SavedAdd your journal

Journals / Arşiv Kaynak Tarama Dergisi / 2015 / Cilt: 24 - Sayı: 4

Current Medical Treatment of StableCoronary Artery Disease

Kararlı Koroner Arter Hastalığında Güncel İlaç Tedavisi

Göknur TEKİN
Abdullah TEKİN
Pages
592–613
Publication Date
2015-09-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review will summarize current recommended pharmacological approachesof stable coronary artery disease, with a focuson novel therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronary artery disease is the leading cause of death in the world.
📊
Key Findings & Data:Despite the increasing success of conventional medical therapies and the continued development and improvement of percutaneous coronary intervention, a significant number of patients with ischemic heart disease and angina pectoris cannot be successfully managed.
💡
Conclusion & Impact:This review will summarize current recommended pharmacological approachesof stable coronary artery disease, with a focuson novel therapies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Kararlı angina · antiiskemik ilaçlar · koroner arter hastalığı

Abstract

Coronary artery disease is the leading cause of death in the world. Despite the increasing success of conventional medical therapies and the continued development and improvement of percutaneous coronary intervention, a significant number of patients with ischemic heart disease and angina pectoris cannot be successfully managed. There are two major purposes in the treatment of stable angina. The first is to prevent myocardial infarction and death and thereby, increase the quantity of life. The second is to reduce symptoms of angina and the frequency and severity of ischemia, which should improve the quality of life. Antiischemic agents, including beta-blockers, nitrates and calcium channel blockers, remain the mainstay in the prevention of angina. Also new pharmacological options for refractory angina, metabolic agents, and vasodilator therapies are adding to the armamentarium to prevent and treat angina. This review will summarize current recommended pharmacological approachesof stable coronary artery disease, with a focuson novel therapies.

Özet

Koroner arter hastalığı tüm dünyadaki ölümlerin en yaygın sebebidir. Hem tıbbi tedavi, hem de perkütan koroner arter girişimdeki artan yeni gelişmelere rağmen, halen birçok iskemik kalp hastalığı olan hastanın semptomları yeterli düzeyde kontrol altına alınamamaktadır. Kararlı angina tedavisinin iki önemli amacı vardır. Birincisi, miyokard infarktüsü ve ölümü engelleyerek yaşam beklentisini uzatmak, ikincisi de anginanın sıklığını ve şiddetini azaltarak hayat kalitesini arttırmaktır. Beta blokerler, kalsiyum antigonistleri ve nitratlar antiiskemik tedavinin temelini oluştururken, refrakter angina için kullanılan yeni farmakolojik seçenekler, metabolik ajanlar ve vazodilatatör ilaçlar anginanın önlenmesi ve tedavisinde kullanılan silahlar arasına katılmaktadırlar. Bu derlemede kararlı koroner arter hastalığının güncel medikal tedavisi yeni ajanlar ışığı altında özetlenecektir

🔖

Cite This Article

TEKİN, G., TEKİN, A. (2015). Current Medical Treatment of StableCoronary Artery Disease. Arşiv Kaynak Tarama Dergisi, Cilt: 24 - Sayı: 4, 592–613. https://ajindex.com/articles/466076

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-76.
  2. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol. 1972;29:154-63.
  3. Onat A, Uğur M, Tuncer M, Ayhan E, Kaya Z,Küçükdurmaz Z et al.Age at death in the Turkish Adult Risk Factor Study: temporal trend and regional distribution at 56,700 person-years’ follow- up. Türk Kardiyol Dern Arş. 2009;37:155-60.
  4. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006;295:1404–11.
  5. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949- 3003. Ardehali A, Ports TA. Myocardial oxygen supply and demand. Chest. 1990;98:699-705.
  6. Henderson RA, O’Flynn N. Management of stable angina: summary of NICE guidance. Heart. 2012;98:500–7. Robert A. O’Rourke, MD. Alternative strategies for the management of chronic stable angina. Curr Probl Cardiol. 2010;35:384-446.
  7. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49:411–9. Parker J. Nitrates and angina pectoris. Am J Cardiol 1993;73:3C-6C. Nordlander R, Walter M. Once- versus twice-daily administration of controlled-release isosorbide- 5-mononitrate 60mg in the treatment of stable angina pectoris: A randomized, double-blind, cross-over study. Eur Heart J. 1994;15:108-13. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669- 85. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-22.
  8. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S et al. Beta-Blocker use and clinical outcomes in stable outpatients with and w